Breaking News

Valneva Begins COVID Vax Production to Optimize Potential Deliveries

Inactivated, adjuvanted COVID-19 vaccine candidate is in Phase 1/2 clinical development with initial results in April 2021.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Valneva SE began production of its inactivated, adjuvanted COVID-19 vaccine candidate in parallel to the ongoing clinical studies, in an effort to optimize the timeline for potential deliveries of the vaccine. The Phase 1/2 clinical study is fully enrolled and is expected to report initial results in April 2021.   VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe.   In September 2020, Valneva entered a COVID-19 vaccine partnership with ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters